{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=5", "query": { "intervention": "Investigator's Treatment of Choice", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 245, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T19:51:04.009Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06644781", "title": "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan hydrochloride (HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2025-03-27", "completion_date": "2029-11-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Fullerton, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644781" }, { "nct_id": "NCT06205290", "title": "A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "Liso-cel", "type": "BIOLOGICAL" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-16", "completion_date": "2031-10-13", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Duarte, California • Sacramento, California + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT06205290" }, { "nct_id": "NCT06625320", "title": "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RMC-6236", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Liposomal irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-10-16", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 37, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625320" }, { "nct_id": "NCT04697628", "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "tisotumab vedotin", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 502, "start_date": "2021-02-22", "completion_date": "2026-01-15", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 53, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697628" }, { "nct_id": "NCT05639647", "title": "Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gram-negative Bacterial Infections" ], "interventions": [ { "name": "ATM-AVI", "type": "DRUG" }, { "name": "BAT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "9 Months to 17 Years" }, "enrollment_count": 48, "start_date": "2023-04-18", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 3, "location_summary": "San Diego, California • New York, New York", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05639647" }, { "nct_id": "NCT06214052", "title": "VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4524184", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "Antiretroviral therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 22, "start_date": "2024-02-07", "completion_date": "2024-06-12", "has_results": true, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 5, "location_summary": "Bakersfield, California • Los Angeles, California • West Hollywood, California + 2 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06214052" }, { "nct_id": "NCT03662659", "title": "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Cancer of the Stomach", "Esophagogastric Junction" ], "interventions": [ { "name": "BMS-986213", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "XELOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "SOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2018-10-16", "completion_date": "2024-01-18", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 13, "location_summary": "Clovis, California • Duarte, California • La Jolla, California + 10 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662659" }, { "nct_id": "NCT04919226", "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT", "type": "DRUG" }, { "name": "CAPTEM (Capecitabine and Temozolomide)", "type": "DRUG" }, { "name": "Amino-Acid Solution", "type": "OTHER" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2021-12-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 14, "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919226" }, { "nct_id": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2021-03-09", "completion_date": "2027-05", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 46, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 41 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666038" }, { "nct_id": "NCT00488345", "title": "Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Infections", "Intra-Abdominal Infection", "Pneumonia, Bacterial", "Skin Diseases, Bacterial", "Skin Diseases, Infectious" ], "interventions": [ { "name": "Tygacil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "8 Years to 11 Years" }, "enrollment_count": 59, "start_date": "2007-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2012-10-24", "last_synced_at": "2026-10-13T19:51:04.009Z", "location_count": 18, "location_summary": "Long Beach, California • Oakland, California • Orange, California + 15 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488345" } ] }